Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT for High-risk Locally Advanced Rectal Cancer
NCT04543695Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine, oxaliplatin and fluorouracil in rectal cancer (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Rate of tumor down-staging (yp0-II). Started Aug 2020; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatinfluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04543695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543695.